Effects of onabotulinumtoxinA treatment in patients with and without allodynia: results of the COMPEL study

被引：0
|
作者：
William B. Young
J. Ivan Lopez
John F. Rothrock
Amelia Orejudos
Aubrey Manack Adams
Richard B. Lipton
Andrew M. Blumenfeld
机构：
[1] 900 Walnut Street,Jefferson Hospital for Neuroscience
[2] Second Floor,Montefiore Headache Center, Department of Neurology, Department of Epidemiology and Population Health
[3] Suite #200,Headache Center of Southern California
[4] University of South Alabama College of Medicine,undefined
[5] George Washington School of Medicine,undefined
[6] Allergan plc,undefined
[7] Albert Einstein College of Medicine,undefined
[8] The Neurology Center,undefined
来源：
The Journal of Headache and Pain | 2019年 / 20卷
关键词：
COMPEL; onabotulinumtoxinA; Migraine; Allodynia; Disability; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] ADHERENCE TO ONABOTULINUMTOXINA TREATMENT IN PATIENTS WITH SPASTICITY FROM THE ASPIRE STUDY
    Esquenazi, Alberto
    Feng, Wayne
    Wittenberg, George F.
    Gallien, Phillipe
    Baricich, Alessio
    Fanning, Kristina
    Zuzek, Aleksej
    Francisco, Gerard E.
    Bandari, Daniel S.
    TOXICON, 2021, 190 : S23 - S23
  • [42] Results of a study examining the use of onabotulinumtoxinA in pediatric patients with overactive bladder
    Hoebeke, Piet
    Hittelman, Adam
    Jenkins, Brenda
    Geib, Till
    Titanji, Wilson
    Bogaert, Guy
    JOURNAL OF PEDIATRIC UROLOGY, 2024, 20 (04) : 600e1 - 600e8
  • [43] Management and treatment challenges for patients with chronic migraine, application of OnabotulinumtoxinA: early results of 70 patients
    Senturk, A.
    Demiryurek, B. E.
    Uzun, G. Altiokka
    Erdogan, S.
    Omerhoca, S.
    Icen, N. Kale
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 390 - 390
  • [44] OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study
    Rothrock, J. F.
    Lipton, R. B.
    Young, W. B.
    Jo, E.
    Adams, Manack A.
    Blumenfeld, A. M.
    HEADACHE, 2019, 59 : 34 - 35
  • [45] OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontinue Topiramate: Results of the FORWARD Study
    Rothrock, John F.
    Lipton, Richard B.
    Young, William B.
    Jo, Esther
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    CEPHALALGIA, 2019, 39 : 243 - 244
  • [46] OnabotulinumtoxinA Is Safe and Effective in Patients Who Discontiune Topiramate: Results of the FORWARD Study
    Rothrock, John F.
    Lipton, Richard B.
    Young, William B.
    Jo, Esther
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    NEUROLOGY, 2019, 92 (15)
  • [47] Long-term safety and efficacy of onabotulinumtoxinA for the prevention of chronic migraine in a South Korean population: COMPEL study
    Kim, Byung-Kun
    Chu, Min Kyung
    Adams, Aubrey Manack
    Blumenfeld, Andrew M.
    NEUROLOGY ASIA, 2019, 24 (02) : 127 - 137
  • [48] OnabotulinumtoxinA treatment for spasticity reduces disability outcomes in treatment-naive patients and reduces caregiver burden: results from the ASPIRE study
    Fredericks, M.
    Jost, W. H.
    Ellenbogen, A. L.
    Wittenberg, G. F.
    Ngo, K.
    Largent, J.
    Zuzek, A.
    Francisco, G. E.
    Esquenazi, A.
    INTERNATIONAL JOURNAL OF STROKE, 2019, 14 (4_SUPPL) : 54 - 54
  • [49] OnabotulinumtoxinA is safe and effective in patients who discontinue topiramate: results of the FORWARD study
    Rothrock, J.
    Lipton, R. B.
    Young, W.
    Jo, E.
    Adams, A. Manack
    Blumenfeld, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 806 - 806
  • [50] OnabotulinumtoxinA treatment in adults with spasticity reduces caregiver burden: Results from the ASPIRE study
    Esquenazi, A.
    Ellenbogen, A.
    Wittenberg, G.
    Ngo, K.
    Largent, J.
    Zuzek, A.
    Francisco, G.
    Jost, W.
    MOVEMENT DISORDERS, 2019, 34 : S557 - S557
12345